Earnings release
Page 1
RNS Number : 4996SRenalytix PLC11 February 2026 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION ASSTIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OFTHE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THISINSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Renalytix plc("Renalytix" or the "Company") H1 Trading update LONDON and NEW YORK, 11 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precisionmedicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved andMedicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetickidney disease, provides a trading update for the six months ended 31 December 2025 ("H1 FY26"). Current trading · H1 FY26 unaudited revenues of $1.6m and FY26 revenue guidance of $4m to 30 June 2026 (up 33% YoY). · Three new integrations implemented in H1 FY26, compared to one in FY25, with additional integrations expected in H2 FY26. Revenue acceleration in H2 FY26 from recent integrations. · New large-scale hospital group integration, with an initial proposed 1,000 patient pilot in 2026, and potential to reach over 40,000 CKD patients. Real World Evidence Study · Renalytix is advancing an innovative real-world evidence (RWE) study designed to further validate and expand the clinical and economic utility of kidneyintelX.dkd in kidney and cardiovasculardisease management. The programme is expected to generate unique outcomes data to supportbroader clinical adoption, payer engagement, and strengthening the strategic positioning ofkidneyintelX.dkd within population health and value-based care frameworks. · As part of this study, kidneyintelX.dkd is expected to be integrated into up to five additional large healthcare organisations electronic medical record (EMR) systems, which would expandautomated patient identification and testing access through deployment into routine clinicalworkflows. · To support the RWE study, Renalytix is also in discussion with larger strategic partners regarding potential investment and/or logistics support, reflecting external interest in the programme andits ability to drive scalable clinical and commercial impact. Trading updateH1 FY26 unaudited revenues were $1.6m. Revenue ramp-up during H1 FY26 was slower thanexpected due to longer lead times and complexities with larger healthcare system electronic medicalrecord system (EMR) implementations. As announced on 12 January 2026, three new US healthcare provider groups have now beenintegrated with EMR test ordering capabilities, with an additional three integrations on boarding inthe current quarter. This additional test distribution will contribute to FY26 revenues during thesecond half of the financial year. FY26 full year revenues are now expected to be circa $4.0m (FY25$3.0m). The sales pipeline that is currently being onboarded will significantly expand the EMRintegrated testing footprint of kidneyintelX.dkd in 2026 and provide multiple opportunities with largehealthcare systems in western and eastern United States. The Company is in implementation planning stage for a new large-scale integration, with an initialproposed 1,000 patient pilot in 2026 at one of the largest regional healthcare systems in the US. When fully completed, this has the potential to be one of the larger patient populations to haveaccess to kidneyintelX.dkd, which has full reimbursement by Medicare at $950 per reportable result.Further announcements regarding the integration and pilot study will be made as soon as practicable.
Page 2
Continued progress with Tempus AI CollaborationRenalytix continues to make progress with Tempus AI, Inc. ("Tempus") to advance EMR-integratedtesting and data collection with other US healthcare providers. A joint working group, established aspart of the previously announced collaboration with Tempus AI, is discussing the value of combiningadvanced AI enabled diagnostics offering in kidney disease and cardiovascular disease. Renalytixbelieves this represents a unique opportunity for the partnership to take a leadership position in theCardio-Kidney-Metabolic (CKM) health initiative, which affects up to 80% of the diabetic kidney disease population1. Further operational improvements and cost savingsDuring H1 FY26, the Company activated the relocation of its laboratory operations, with the newfacility to become fully operational during H2 FY26. This move should significantly increase testingcapacity and deliver over $1m of operating cost savings over the next five years, supporting bothgrowth and operational efficiency. The Company continues to focus on and implement cost reductioninitiatives and maintained a cash balance of approximately $6 million as of 31 December 2025. Additional supportive data expected before financial year endThe Company continues to generate and publish data on the clinical and operational value ofkidneyintelX.dkd, including a recently announced manuscript in Diabetes Care. A major milestone hasbeen reached with finalization of the two-year clinical outcome data now being prepared forsubmission for peer-reviewed publication. The public read-out of this is anticipated before the end ofthe fiscal year and is expected to be an important asset in supporting clinical adoption and informingnational commercial insurance payment coverage. Renalytix anticipates providing an overview of the update in an online presentation via Investor MeetCompany and will provide details in due course. The Company will announce its unaudited interimresults for the six months ended 31 December 2025 before the end of March 2026. Notes1 Arnold SV, Kosiborod M, Wang J et a., Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within thediabetes collaborative registry. Diabetes. Obe Metab. 2018;20:2000-2003. For further information, please contact: Renalytix plc www.renalytix.comJames McCullough, CEO Via Walbrook PR SP Angel Corporate Finance LLP (Nominated Adviser andJoint Broker) Tel: +44 (0)20 3470 0470 Jeff Keating / David Hignell (Corporate Finance)Vadim Alexandre (Corporate Broking) Oberon Capital (Joint Broker) Tel: +44 (0)20 3179 5300Mike Seabrook / Nick Lovering Walbrook PR Limited Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.comPaul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804654 About Renalytix (www.renalytix.com)Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnosticscompany, focused on optimizing clinical management of kidney disease to drive improved patientoutcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkdwhich is now offered commercially in the United States. Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers tocontrolling cost and suffering in the United States and the United Kingdom's medical system,affecting approximately 15 million and 8 million people, respectively. After five years of developmentand clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed prognostictool capable of understanding a patient's risk with diabetic kidney disease early where treatment hasmaximal effect. kidneyintelX.dkd is now being deployed across large physician group practices andhealth systems in select regions of the United States. The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial bodyof real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, ademonstrated and significant increase in diagnosis, prognosis, and treatment rates have beenrecorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurancepayer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended foruse in the international chronic kidney disease clinical guidelines (KDIGO).
Page 3
KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI,Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, theIcahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about thekidneyintelX,dkd test, visit kidneyintelx.com. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authorityto act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informationmay apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the informationcontained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. Forfurther information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END